Menu Search
Equities

Bristol-Myers Squibb Co

BRM:HAN

Bristol-Myers Squibb Co

Actions
  • Price (EUR)55.97
  • Today's Change-0.300 / -0.53%
  • Shares traded80.00
  • 1 Year change+24.10%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

  • Revenue in USD (TTM)47.44bn
  • Net income in USD-7.26bn
  • Incorporated1933
  • Employees34.10k
  • Location
    Bristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
  • Phone+1 (609) 252-4621
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BMY:NYQ since
announced		Transaction
value
RayzeBio IncDeal completed26 Dec 202326 Dec 2023Deal completed12.41%4.21bn
Karuna Therapeutics IncDeal completed22 Dec 202322 Dec 2023Deal completed14.67%14.40bn
Data delayed at least 15 minutes, as of Nov 26 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.